Abstract:ObjectiveRheumatoid arthritis (RA) is the most common form of autoimmune inflammatory arthritis. Intra-articular gene delivery to block proinflammatory cytokines has been studied in pre-clinical models and human clinical trials. It has been demonstrated that the level of programmed death-ligand 1 (PD-L1) is associated with rheumatoid arthritis (RA). This study examined the therapeutic role of PD-L1 by intra-articular delivery via adeno-associated virus (AAV) vectors in the mouse collagen-induced arthritis (CIA) model.MethodsMice were intra-articularly injected with AAV5 vectors encoding human PD-L1 on day 0 and immunized with bovine type II collagen to induce CIA simultaneously. On day 49 post AAV administration, joints were collected for histo-pathological and cytokine analysis. Additionally, the systemic impacts of intra-articular injection of AAV5/PD-L1 vectors were also studied. To study the therapeutic effect of PD-L1, AAV5/PD-L1 vectors were administered into the joints of RA mice on day 21.ResultsAfter administration of AAV5/PD-L1 vectors, strong PD-L1 expression was detected in AAV transduced joints. Joints treated with PD-L1 at the time of arthritis induction exhibited significantly less swelling and improved histopathological scores when compared to untreated joints. Additionally, the infiltration of T cells and macrophages was decreased in joints of CIA mice that received AAV5/PD-L1 vectors (P<0.05). The levels of pro-inflammatory cytokines, including IL-1, IL-6, IL-17 and TNFα, were lower in AAV5/PD-L1 treated than untreated joints (P<0.05). Furthermore, the administration of AAV5/PD-L1 vectors into the joints of CIA mice did not impact serum cytokine levels and the antibody titers to type II collagen. Biodistribution of AAV vectors after intra-articular injection showed undetectable AAV genomes in other tissues except for a low level in the liver. Similar to the results of AAV5/PD-L1 vector administration on day 0, decreased joint swelling and lower histopathological damage were observed in joints treated with AAV5/PD-L1 vectors on day 21.ConclusionThe results from this study demonstrate that local AAV mediated PD-L1 gene delivery into the joints is able to prevent the development and block the progression of arthritis in CIA mice without impacting systemic immune responses. This study provides a novel strategy to effectively treat inflammatory joint diseases using local AAV gene therapy by interference with immune checkpoint pathways.

Vaccination by Two DerG LEAPS Conjugates Incorporating Distinct Proteoglycan (PG, Aggrecan) Epitopes Provides Therapy by Different Immune Mechanisms in a Mouse Model of Rheumatoid Arthritis

Therapeutic Vaccination of Active Arthritis with a Glycosylated Collagen Type II Peptide in Complex with MHC Class II Molecules

A Single Microorganism Epitope Attenuates the Development of Murine Autoimmune Arthritis: Regulation of Dendritic Cells via the Mannose Receptor

N-Glycosylated Type II Collagen Peptides As Therapeutic Saccharide Vaccines for Rheumatoid Arthritis

Tolerance induction using lentiviral gene delivery delays onset and severity of collagen II arthritis.

Design Of Glycopeptides Used To Investigate Class Ii Mhc Binding And T-Cell Responses Associated With Autoimmune Arthritis

Therapeutic Effect of Ergotope Peptides on Collagen-Induced Arthritis by Downregulation of inflammatory and Th1/Th17 Responses and Induction of Regulatory T Cells

Therapy Targeting Antigen-Specific T Cells by a Peptide-Based Tolerizing Vaccine Against Autoimmune Arthritis.

A fructosylated peptide derived from a collagen II T cell epitope for long-term treatment of arthritis (FIA-CIA) in mice

Vaccines prevent reinduction of rheumatoid arthritis symptoms in collagen-induced arthritis mouse model

Protective Effects of Overexpression TCR Vbeta5.2-HSP70 and TCR Vbeta8.2-HSP70 Against Collagen-Induced Arthritis in Rats.

Autoantigen‐dexamethasone Conjugate‐Loaded Liposomes Halt Arthritis Development in Mice

Current status of immunological therapies for rheumatoid arthritis with a focus on antigen-specific therapeutic vaccines

Mucosal administration of an altered CII263-272 peptide inhibits collagen-induced arthritis by suppression of Th1/Th17 cells and expansion of regulatory T cells

Glycopeptide Specificity of Helper T Cells Obtained in Mouse Models for Rheumatoid Arthritis

Intra-articular Delivery of AAV Vectors Encoding PD-L1 Attenuates Joint Inflammation and Tissue Damage in a Mouse Model of Rheumatoid Arthritis

Predominant Selection of T Cells Specific for the Glycosylated Collagen Type II Epitope (263-270) in Humanized Transgenic Mice and in Rheumatoid Arthritis.

Therapeutic Effects of IL-1RA, M2 Cells, and Their Synergistic Impact on a Mouse Model of Rheumatoid Arthritis

Antigen-Specific Gene Therapy after Immunisation Reduces the Severity of Collagen-Induced Arthritis

A Citrullinated Antigenic Vaccine in Treatment of Autoimmune Arthritis

A Single Functional Group Substitution In C5a Breaks B Cell And T Cell Tolerance And Protects Against Experimental Arthritis